Treatment of microbial infections with bacterial proteins and peptides
AssigneeUrex Biotech, Inc.
InventorsJeffrey Howard, Gregor Reid, Bing Siang Gan
Life of this patent
Estimating the term…
Abstract
The present invention relates to protein and peptide chemistry. In particular, the present invention relates to the discovery and isolation of novel peptides whose sequences derive from microorganism by-products including biosurfactants. The invention is also directed to the use of these novel peptides in the inhibition of infections caused by pathogens.
Claims14
An isolated biosurfactant peptide comprising Xaa1,-Gln-Gly-Xaa2-val-Ser-Xaa3-Xaa4-Gly-Ser-Cys-Thr-Cys-Ala-Gln-Lys (SEQ ID NO:
- 1), wherein Xaa1, and Xaa2 is any amino acid and Xaa3 and Xaa4 are selected from the group consisting of Phe or Ala.
An isolated biosurfactant peptide comprising Leu-Gln-Gly-Leu-Val-Ser-Xaa3-Xaa4-Gly-Ser-Cys-Thr-Cys-Ala-Gln-Lys (SEQ ID NO:
- 1), and Xaa3 and Xaa4 are selected from the group consisting of Phe or Ala.
An isolated biosurfactant peptide comprising Glu-val-Tyr-Xaa1-Phe-Gln-Glu-Xaa2-Xaa3-Arg (SEQ ID NO:
- 2), wherein Xaa1, is any amino acid and Xaa2 and Xaa3 are selected from the group consisting of Gln or Pro.
An isolated biosurfactant peptide comprising Trp-Asn-Tyr-Val-Ser (SEQ ID NO:
- 3).
An isolated biosurfactant peptide comprising Arg-Ala-Phe-Ala-Xaa1,-Xaa2-Ser-Asn-Trp-Pro-Val-Lys (SEQ ID NO:
- 4), wherein Xaa1and Xaa2 can be any amino acid.
An isolated biosurfactant peptide comprising Gly-Xaa1-Gln-Xaa2-Xaa3-Asp-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Arg (SEQ ID NO:
- 5), wherein Xaa1, Xaa2, Xaa3 and Xaa4 can be any amino acid and Xaa5, Xaa6, Xaa7, and Xaa8 are selected from the group consisting of Ser or His.
An isolated biosurfactant peptide comprising Gly-Xaa1,-Gln-Asn-Asp-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Arg (SEQ ID NO:
- 6), wherein Xaa1, and Xaa2 is any amino acid and Xaa3 Xaa4, Xaa5 and Xaa6 are selected from the group consisting of Ser or His.
A biosurfactant peptide.
A pharmaceutical composition comprising a biosurfactant peptide and a pharmaceutically acceptable carrier.
A method of inhibiting an infection comprising blocking the interaction of a pathogen with a collagen receptor by the administration of a biosurfactant peptide.
Dependencies are inferred from the claim text.